Michael C Bibby
Overview
Explore the profile of Michael C Bibby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duncan R, Sat-Klopsch Y, Burger A, Bibby M, Fiebig H, Sausville E
Cancer Chemother Pharmacol
. 2013 Jun;
72(2):417-27.
PMID: 23797686
Purpose: Intravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability and retention (EPR) effect, but in vivo tumour models are rarely calibrated with respect...
2.
Veiga J, Cooper P, Pors K, Patterson L, Bibby M, Shnyder S
J Pharmacol Toxicol Methods
. 2011 May;
64(3):226-32.
PMID: 21569858
Introduction: The preclinical development and clinical progression of potential anticancer agents are highly time and resource-intensive. Traditionally, promising compounds in vitro undergo further screening in xenograft models, a long process...
3.
Prokopiou E, Cooper P, Pettit G, Bibby M, Shnyder S
Mol Med Rep
. 2011 Apr;
3(2):309-13.
PMID: 21472238
Dolastatin 10, a marine natural product peptide, is now known to act as a vascular disrupting agent (VDA). These VDA properties were not known when other aspects of its promising...
4.
Atkinson J, Falconer R, Edwards D, Pennington C, Siller C, Shnyder S, et al.
Cancer Res
. 2010 Jul;
70(17):6902-12.
PMID: 20663911
Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic...
5.
Shnyder S, Cooper P, Millington N, Gill J, Bibby M
J Nat Prod
. 2007 Dec;
71(3):321-4.
PMID: 18154271
Sodium pancratistatin 3,4- O-cyclic phosphate ( 2) is a novel water-soluble synthetic derivative of pancratistatin ( 1), a natural alkaloid constituent of Amaryllidaceae plants, that exhibits good cytostatic and antineoplastic...
6.
Shnyder S, Cooper P, Millington N, Pettit G, Bibby M
Int J Oncol
. 2007 Jul;
31(2):353-60.
PMID: 17611692
Despite promising early data, the natural product dolastatin 10 has not been successful as a single agent in phase II clinical trials. Herein the mechanism of action and efficacy of...
7.
Suggitt M, Cooper P, Shnyder S, Bibby M
Int J Oncol
. 2006 Nov;
29(6):1493-9.
PMID: 17088988
We describe a modified hollow fibre assay (HFA) for investigating the potential of novel molecules as pharmaceutical agents. In particular the assay provides drug/target interaction data that can facilitate the...
8.
Pletsas D, Wheelhouse R, Pletsa V, Nicolaou A, Jenkins T, Bibby M, et al.
Eur J Med Chem
. 2006 Feb;
41(3):330-9.
PMID: 16458393
The protein O6-alkylguanine-DNA alkyltransferase (Atase) is responsible for the repair of DNA lesions generated by several clinically important anti-cancer drugs; this is manifest as active resistance in those cancer cell...
9.
Pettit G, Minardi M, Rosenberg H, Hamel E, Bibby M, Martin S, et al.
J Nat Prod
. 2005 Oct;
68(10):1450-8.
PMID: 16252907
The present SAR study of combretastatin A-3 (3a) focused on replacement of the 3-hydroxyl group by a series of halogens. That approach with Z-stilbenes resulted in greatly enhanced (>10-100-fold) cancer...
10.
Seargent J, Loadman P, Martin S, Naylor B, Bibby M, Gill J
Urology
. 2005 Apr;
65(4):815-20.
PMID: 15833553
Objectives: To analyze matrix metalloproteinase-10 (MMP-10) expression in transitional cell carcinoma (TCC) of the bladder, evaluate the correlations between MMP-10 protein expression and clinicopathologic parameters, and address the viability of...